Literature DB >> 10533459

ATM heterozygote cells exhibit intermediate levels of apoptosis in response to streptonigrin and etoposide.

D Pernin1, J O Bay, N Uhrhammer, Y J Bignon.   

Abstract

Ataxia-telangiectasia (A-T) is a rare recessive disease characterised by cerebellar ataxia, immunodeficiency, sensitivity to ionising radiation and increased cancer risk. Heterozygotes have an increased risk of cancer and may comprise 1% of the population. In vitro, A-T heterozygote cell lines show radiosensitivity intermediate between normal and A-T homozygotes. Furthermore, in A-T homozygotes, hypersensitivity to chemical agents which cause DNA damage, similar to that produced by ionising radiation, has been observed. To investigate the chemosensitivity of A-T heterozygote cell lines, we used TUNEL to analyse the level of apoptosis after drug treatment with etoposide and streptonigrin. Our samples included four normal, eight A-T heterozygote and 10 A-T homozygote lymphoblastoid cell lines. All cell lines were exposed to drugs for 24 h, then cultivated in fresh media for 0 and 72 h. The levels of apoptosis increased significantly in all cell lines, with the greatest increase in homozygote cells and an intermediate increase in heterozygote cells (P values of < 0.01 for etoposide treatment and < 0.02 for streptonigrin treatment were obtained using the Kruskal-Wallis H-test). Our results indicate that A-T heterozygotes express intermediate sensitivity to etoposide and streptonigrin similar to that observed in response to ionising radiation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10533459     DOI: 10.1016/s0959-8049(99)00059-3

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  1 in total

1.  Gene expression signatures but not cell cycle checkpoint functions distinguish AT carriers from normal individuals.

Authors:  Liwen Zhang; Dennis A Simpson; Cynthia L Innes; Jeff Chou; Pierre R Bushel; Richard S Paules; William K Kaufmann; Tong Zhou
Journal:  Physiol Genomics       Date:  2013-08-13       Impact factor: 3.107

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.